FindTrial
Sign In

PX-866

DRUG6 trials

Sponsors

Cascadian Therapeutics Inc., NCIC Clinical Trials Group

Conditions

Advanced BRAF-mutant CancersAdvanced Solid TumorsGlioblastomaHealthy VolunteerNon Small Cell Lung Cancer (NSCLC)Prostate CancerSquamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 1

Phase I Trial of Oral PX-866
CompletedNCT00726583
Cascadian Therapeutics Inc.Advanced Solid Tumors
Start: 2008-06-30End: 2011-09-30Target: 90Updated: 2018-05-17
Study of PX-866 and Docetaxel in Solid Tumors
CompletedNCT01204099
Cascadian Therapeutics Inc.Non Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Start: 2010-09-30End: 2014-02-28Updated: 2018-05-16
Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers
CompletedNCT01408316
Cascadian Therapeutics Inc.Healthy Volunteer
Start: 2011-07-31End: 2012-01-31Updated: 2018-05-17
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
TerminatedNCT01616199
Cascadian Therapeutics Inc.Advanced BRAF-mutant Cancers
Start: 2012-08-31End: 2015-03-31Updated: 2018-05-16

Phase 2

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
CompletedNCT01259869
NCIC Clinical Trials GroupGlioblastoma
Start: 2011-04-01End: 2015-02-13Updated: 2023-08-22
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
CompletedNCT01331083
NCIC Clinical Trials GroupProstate Cancer
Start: 2011-09-09End: 2015-11-27Updated: 2023-08-22

Related Papers

IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.
Journal of Clinical Oncology2015-03-014 citations